Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,155.80 +28.01 (+0.55%) Dow
38,707.37 +31.69 (+0.08%) Nasdaq
16,268.09 +111.76 (+0.69%) Bitcoin USD
63,412.54 -902.51 (-1.40%) CMC Crypto 200
1,362.71 +50.08 (+3.81%)
BNTX Jun 2024 110.000 call
| Previous close | 0.5000 |
| Open | 0.3500 |
| Bid | 0.2500 |
| Ask | 0.4500 |
| Strike | 110.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.3500 - 0.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 295 |
Barrons.comBioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.
- Reuters
UPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of year
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.
ReutersBioNTech says 90% of 2024 revenues will accrue at end of year
FRANKFURT (Reuters) -Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.
